Skip to main content
Top

Arthritis Research & Therapy

Issue 2/2000

Content (9 Articles)

Commentary

A new model for rheumatoid arthritis?

Hugh McDevitt

Commentary

What can we do about osteoarthritis?

L Stefan Lohmander

Review

Death, autoantigen modifications, and tolerance

Paul J Utz,, Timothy J Gensler, Paul Anderson

Review

B cells in rheumatoid arthritis

Hye-Jung Kim, Claudia Berek

Open Access Research article

Acute-phase serum amyloid A production by rheumatoid arthritis synovial tissue

Rosemary O'Hara, Evelyn P Murphy, Alexander S Whitehead, Oliver FitzGerald, Barry Bresnihan

Open Access Research article

Active synovial matrix metalloproteinase-2 is associated with radiographic erosions in patients with early synovitis

Raphaela Goldbach-Mansky, Jennifer M Lee, Joseph M Hoxworth, David Smith II, Paul Duray, H Ralph Schumacher Jr, Cheryl H Yarboro, John Klippel, David Kleiner, Hani S El-Gabalawy

Open Access Research article

Specificity of T cells in synovial fluid: high frequencies of CD8+ T cells that are specific for certain viral epitopes

Linda C Tan, Alastair G Mowat, Chrysoula Fazou, Tim Rostron, Helen Roskell, P Rod Dunbar, Claire Tournay, François Romagné, Marie-Alix Peyrat, Elisabeth Houssaint, Marc Bonneville, Alan B Rickinson, Andrew J McMichael, Margaret FC Callan

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine